News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Philadelphia Business Journal Features Liz Magill and her Innovation Goals
In an interview about her long-term vision for the university with the Philadelphia Business Journal, Penn President Liz Magill mentions Penn’s breakthroughs in cell and gene therapy.
Philadelphia ranks as one of the top five most active regions for venture capital in 1Q
According to the latest Pitchbook-NVCA Venture Monitor report, the Greater Philadelphia area ranked fifth in the U.S. for the most closed venture capital deals in 2022 and the start of 2023.
REGENXBIO Receives FDA Fast Track Designation for its Novel Gene Therapy Candidate
Penn spinout REGENXBIO received FDA Fast Track designation for its novel gene therapy candidate RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne muscular dystrophy.
Penn and PCI recognized in the Daily Pennsylvanian for licensing income and spinout companies
Penn was highlighted in The Daily Pennsylvanian for ranking first in annual licensing income among 153 research institutions.
Bruce Levine Speaks on the Future of CAR-T Therapies
Levine explained that there are currently six approved CAR-T therapies and he estimates that between 25,000 and 30,000 patients have been treated with those therapies globally.
Penn I-Corps Launches Spring 2023 cohort
The cohort started at the end of February and is underway. Teams are currently engaged in reaching out and conducting Customer discovery interviews.
PCI Promotes Innovation and Startups at the South by Southwest (SXSW) annual Interactive Conference
It was a great opportunity to share the innovation initiatives coming out of Penn and Philadelphia with a global audience.
PCI Featured as the Philadelphia Business Journal Cover Story
This in-depth interview with Swartley provides a comprehensive history about technology transfer at Penn as well as the establishment and current success of PCI.
Ligand-tethered Lipid Nanoparticles for Targeted RNA Delivery to Treat Liver Fibrosis
the Mitchell Lab has developed a new class of anisimide-functionalized lipids that enables targeted delivery of lipid nanoparticles (LNPs) to activated fibroblasts in the liver.
Penn Ranks First in Licensing Income
Penn officially ranked number one in terms of licensing income in the latest Association of University Technology Managers (AUTM) annual survey, which included 153 reporting institutions.